Zipper-interacting protein kinase (ZIPK) is a widely expressed serine/threonine kinase implicated in cell death and smooth muscle contractility, but its mechanism of regulation is unknown. We have identified six phosphorylation sites in ZIPK that regulate both its enzyme activity and localization, including 299 and Thr 300 to alanine resulted in redistribution of ZIPK from the cytosol to the nucleus. Mutation of Thr 299 alone to alanine caused ZIPK to assume a diffuse cellular localization, whereas T299D redistributed the enzyme to the cytoplasm. Cterminal truncations of ZIPK at amino acid 273 or 342 or mutation of the leucine zipper motif increased ZIPK activity toward exogenous substrates by severalfold, suggesting a phosphorylation-independent autoinhibitory role for the C-terminal domain. Additionally, mutation of the leucine zipper reduced the ability of ZIPK to oligomerize and also caused ZIPK to relocalize from the cytoplasm to the nucleus in vivo. Together, our findings show that ZIPK is positively regulated by phosphorylation within its kinase domain and that it contains an inhibitory C-terminal domain that controls enzyme activity, localization, and oligomerization.
in the substrate-binding groove, and Thr 265 in kinase subdomain X is essential for full ZIPK autophosphorylation and activity toward exogenous substrates. Abrogation of phosphorylation of Thr 299 , Thr 306 , and Ser 311 had little effect on enzyme activity, but mutation of Thr 299 and Thr 300 to alanine resulted in redistribution of ZIPK from the cytosol to the nucleus. Mutation of Thr 299 alone to alanine caused ZIPK to assume a diffuse cellular localization, whereas T299D redistributed the enzyme to the cytoplasm. Cterminal truncations of ZIPK at amino acid 273 or 342 or mutation of the leucine zipper motif increased ZIPK activity toward exogenous substrates by severalfold, suggesting a phosphorylation-independent autoinhibitory role for the C-terminal domain. Additionally, mutation of the leucine zipper reduced the ability of ZIPK to oligomerize and also caused ZIPK to relocalize from the cytoplasm to the nucleus in vivo. Together, our findings show that ZIPK is positively regulated by phosphorylation within its kinase domain and that it contains an inhibitory C-terminal domain that controls enzyme activity, localization, and oligomerization.
Zipper-interacting protein kinase (ZIPK)
1 is a serine/threonine protein kinase that has been functionally linked to cell motility (1), smooth muscle contractility (2) (3) (4) , and cell death processes (5, 6) . ZIPK is a member of a larger family of protein kinases known as the death-associated protein kinases, which include DAPK, DRP-1 (DAPK-related protein-1), DRAK1, and DRAK2 (7) . ZIPK itself is composed of an N-terminal protein kinase domain and a C-terminal domain that contains a leucine zipper motif. ZIPK shares 80% identity within its kinase domain with DAPK, but shows no homology in its Cterminal domain to other DAPK family members and, in contrast to DAPK, does not contain a death or calmodulin-binding domain, and its activity is regulated independently of calcium (8) .
Like other members of the DAPK family, ZIPK causes cell death upon overexpression in a variety of cell types, suggesting that the enzyme may play a role in apoptosis (5, 6, 9) . Cells that overexpress ZIPK typically show signs of rounding, membrane blebbing, DNA fragmentation, and detachment from the matrix. However, it remains unclear what the mechanism of cell death is since some indicators of apoptosis, such as caspase-3 activation and poly(ADP-ribose) polymerase cleavage, are not associated with ZIPK overexpression (10) . It has been argued that cell death induced by ZIPK and other DAPK family members may be a result of autophagy as opposed to apoptosis (10) . Some insight into the phenotype caused by the overexpression of ZIPK may be gained from studying its candidate substrate proteins. Like other members of the DAPK family, ZIPK is capable of phosphorylating smooth muscle and non-muscle myosin light chains (1) (2) (3) 11) . Indeed, phosphorylation of myosin light chain is known to cause reorganization of the actin cytoskeleton, and this could explain, at least in part, some of the cellular phenotypes observed with ZIPK overexpression such as membrane blebbing and cell rounding (13, 14) .
ZIPK has also been implicated in smooth muscle contraction and relaxation. Smooth muscle contraction is regulated by the phosphorylation state of myosin light chain, which is regulated, in part, by the myosin light chain phosphatase SMPP-1M (15) . SMPP-1M is a phosphoprotein, and phosphorylation of at least two sites (Thr 696 and Ser 850 ) within its 110 -130-kDa regulatory subunit, MYPT1 (myosin phosphatase targeting subunit-1), inhibits phosphatase activity (2, 16 -19) . MYPT1 is phosphorylated and inhibited during calcium sensitization, a process in which muscle contraction occurs at constant concentrations of calcium (20) . To better understand how SMPP-1M is regulated, a proteomics approach was performed to identify protein kinases in smooth muscle capable of phosphorylating MYPT1. A protein kinase that associated with and phosphorylated Thr 696 of MYPT1 was identified as a fragment of ZIPK (2). More recently, it was shown that ZIPK is the major MYPT1-associated kinase in smooth muscle aortic cells (4) . Other targets for ZIPK in smooth muscle that may contribute to the Ca 2ϩ -sensitizing effects of the enzyme, including the SMPP-1M inhibitor protein CPI-17 (21) and myosin light chain itself (1, 2, 12) , have also been identified. Direct evidence in support of a role for ZIPK in Ca 2ϩ sensitization has come from experiments showing that addition of the purified recombinant enzyme to Triton X-100-skinned muscle fibers causes profound contraction at submaximal Ca 2ϩ concentrations (3). Although the mechanism of ZIPK regulation is unknown, evidence suggests that ZIPK is regulated by phosphorylation in vivo. First, ZIPK phosphorylation and activity are increased in smooth muscle in response to carbachol (2) . Second, treatment of ZIPK with protein phosphatase inactivates the enzyme (12) . Third, ZIPK can be phosphorylated by DAPK in vitro, and this phosphorylation was reported to control the localization of ZIPK and to affect its ability to induce cell death (10) . Finally, ZIPK autophosphorylates in vitro (2, 5) . However, the phosphorylation sites and their functional significance have not been determined.
We have undertaken a comprehensive study to identify ZIPK phosphorylation sites in vitro and in vivo and to determine their physiological relevance. We defined six sites of phosphorylation within ZIPK that regulate both its activity and localization within cells. We show that three sites in the conserved kinase domain (Thr 180 , Thr 225 , and Thr 265 ) are essential for kinase activation, whereas phosphorylation of three sites in the C-terminal domain (Thr 299 , Thr 306 , and Ser 311 ) has little effect on enzyme activity toward exogenous substrates. However, phosphorylation of ZIPK at Thr 299 regulates the intracellular location of ZIPK. Collectively, these results demonstrate that ZIPK is highly regulated by multisite phosphorylation, and since five of the identified phosphorylation sites in ZIPK are conserved in other DAPK family members, our findings may have implications for the regulation of these highly related enzymes.
EXPERIMENTAL PROCEDURES

Materials-[␥-
32 P]ATP was obtained from MP Biomedicals (Irvine, CA). ANTI-FLAG® M2 monoclonal antibody, 3X FLAG® peptide, and ANTI-FLAG® M2 antibody affinity gel were obtained from Sigma. Sequencing grade modified porcine trypsin (V5111) was from Promega, and chymotrypsin was obtained from Calbiochem. Anti-ZIPK antibodies directed against amino acids 279 -298 were from Calbiochem, and anti-c-Myc antibody 9E10-agarose and anti-c-Myc (A-14) antibodies were from Santa Cruz Biotechnology.
Plasmid Construction-For 3X FLAG-ZIPK, full-length human ZIPK was amplified by PCR using the following primers (which contain HindIII and BamHI sites, respectively): forward primer, AGTCAAGC-TTTCCACGTTCAGGCAGGAGGAC; and reverse primer, CAGTGGAT-CCCTAGCGCAGCCCGCACTCCAC. The PCR product was digested with HindIII and BamHI and ligated into the corresponding sites in the p3XFLAG-CMV-10 expression vector (Sigma). This vector encodes three adjacent FLAG epitopes with the N-terminal sequence MDYK-DHDGDYKDHDIDYKDDDDK preceding ZIPK. For Myc-ZIPK, fulllength human ZIPK was amplified by PCR using the following primers (which contain XhoI and BamHI sites, respectively) to incorporate a Myc tag: forward primer, TGCACTCGAGATGGCAGAACAGAAGCTC-ATTTCTGAAGAAGACTTGTCCACGTTCAGGCAGGAGGAC; and reverse primer, CAGTGGATCCCTAGCGCAGCCCGCACTCCAC. The PCR product was digested with XhoI and BamHI and ligated into the corresponding sites in pcDNA3.1 (Invitrogen). This strategy encodes a Myc tag with the N-terminal sequence MAEQKLISEEDL preceding ZIPK.
Site-directed Mutagenesis-All ZIPK mutants were created with the QuikChange mutagenesis kit (Stratagene) and completely sequenced for confirmation.
Cell Culture, Transfections, and Expression and Purification of ZIPK-HeLa and human embryonic kidney 293 (HEK293) cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% bovine calf serum. Transfections were performed using Superfect (QIAGEN Inc.) according to the manufacturer's instructions. For expression of ZIPK, four 100-cm dishes of HEK293 cells were transfected with ZIPK DNA and incubated for 48 h. Cells were harvested and homogenized in cell lysis buffer containing 50 mM TrisHCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 1 mM dithiothreitol, 2 mM EDTA, 1 g/ml leupeptin, 1 g/ml aprotinin, and 100 g/ml Pefabloc. Cell lysates were clarified by centrifugation for 15 min at 13,000 ϫ g, and the supernatant was mixed with ANTI-FLAG® M2 antibody affinity gel for 1 h at 4°C. The ANTI-FLAG® M2 antibody affinity gel was then washed four times with cell lysis buffer and two times with Tris-buffered saline before elution of ZIPK with 150 M 3X FLAG® peptide in Tris-buffered saline.
In P]ATP (specific activity of 394,800 cpm/nmol) for 10 min at 37°C before addition of 1 mg of bovine serum albumin and 100 l of 100% trichloroacetic acid. Following incubation on ice for 10 min, the precipitant was collected by centrifugation at 13,000 ϫ g and washed three times with ice-cold 10% trichloroacetic acid before 32 P incorporation was measured by Cerenkov radiation.
Autophosphorylation, HPLC, Edman Degradation, and Phosphoamino Acid Analysis-For autophosphorylation, purified ZIPK was incubated in kinase reaction buffer as described above with 50 M ATP and [␥- 32 P]ATP (Ͼ100,000 cpm/nmol) for 30 min at 30°C. Autophosphorylated ZIPK was resolved by 10% SDS-PAGE, visualized by silver staining, and in gel-digested with trypsin or chymotrypsin (1.5 g) overnight at 37°C. The protein digests were acidified by addition of 0.1% trifluoroacetic acid and applied to a reverse-phase C 18 column (30 ϫ 0.1 cm) equilibrated in 0.1% trifluoroacetic acid. The peptides were eluted from the column with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (0 -60% in 60 min) at a flow rate of 1 ml/min. One-ml fractions were collected, and phosphopeptides were detected by Cerenkov radiation. Selected phosphopeptides were immobilized on Immobilon membrane (Millipore Corp.) according to the manufacturer's instructions and subjected to sequential Edman degradation with a vapor-phase amino acid sequencer (Applied Biosystems Procise 494). Phosphorylation sites were assigned with the aid of the CRP (cleaved radioactive analysis of phosphopeptides) program (available at fasta. bioch.virginia.edu/crp/). Selected phosphopeptides were also subjected to phosphoamino acid analysis. To this end, specific HPLC fractions were incubated with 5.3 M HCl at 100°C for 1 h, followed by evaporation of the acid. Phosphoamino acids were spotted onto thin-layer cellulose plates (Fisher), and electrophoresis was carried out in one dimension for 60 min at 1000 V in buffer containing 5.9% acetic acid, 0.8% formic acid, and 0.3% pyridine at pH 2.5. Phosphoamino acid standards were visualized by spraying with 0.2% ninhydrin in acetone, and 32 P was detected by autoradiography.
Mass Spectrometry-Purified ZIPK from transfected HEK293 cells was in gel-digested with trypsin (0.6 g), and the tryptic peptides were subjected to nanospray electrospray ionization mass spectrometry (ESI-MS) on an Applied Biosystems QSTAR® pulsar mass spectrometer. In some cases, ZIPK tryptic peptides were first resolved by HPLC, and individual fractions were subjected to analysis by ESI-MS. Positive mode time of flight was used to identify ZIPK peptides, and individual peptides were sequenced by ESI-MS/MS using BioAnalyst software.
ZIPK Immunoprecipitation and Immunoblot Analysis-FLAG-ZIPK or Myc-ZIPK was transfected in HEK293 cells, and lysates were prepared as described above. FLAG-ZIPK or Myc-ZIPK was immunoprecipitated with FLAG-agarose or Myc-agarose, respectively, and washed four times with lysis buffer. Immunoprecipitates were boiled in SDS sample buffer, and proteins were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. Nonspecific proteins were blocked with 5% milk in Tris-buffered saline containing 0.1% Tween 20.
Membranes were incubated with ANTI-FLAG® M2 monoclonal antibody (1:10,000) or anti-c-Myc antibody (1:1000), followed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (1:2000; Amersham Biosciences). Proteins were visualized using the ECL chemiluminescence system (Amersham Biosciences).
Indirect Immunofluorescence Microscopy-HeLa cells (10 4 ) were grown on glass coverslips in 35-mm dishes (Fisher) for 24 h and then transfected using Superfect and allowed to grow for an additional 24 h. Coverslips were removed and washed with phosphate-buffered saline (PBS; pH 7.4), and cells were fixed with 2% paraformaldehyde in PBS for 15 min at room temperature. After fixation, cells were permeabilized with 0.1% Triton X-100 in PBS for 15 min and blocked with PBS containing 2% bovine serum albumin and 0.1% Nonidet P-40 for 30 min. After blocking, cells were incubated for 1 h with anti-FLAG antibody diluted 1:1000 in the blocking solution or with anti-c-Myc antibody (1:1000) and then washed three times with PBS containing 0.1% Nonidet P-40 for 10 min. Cells were incubated with Cy3-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratories, Inc.) diluted 1:200 in the blocking solution for 1 h and stained with 4Ј,6-diamidino-2-phenylindole at 0.1 g/ml in 0.1% Nonidet P-40 in PBS. Following washing four times with PBS containing 0.1% Nonidet P-40, coverslips were mounted on glass slides using mounting medium (ProLong antifade kit, Molecular Probes, Inc.) and sealed with nail polish. Cells were imaged with a Zeiss Axioskop fluorescence microscope.
Cell Adherence Assays-HEK293 cells were seeded in 100-cm dishes in triplicate and transfected 24 h later with a combination of ZIPK DNA (14 g) and enhanced green fluorescent protein (GFP) DNA (2 g). At 24 h after transfection, the medium was harvested, and the unattached cells were collected by centrifugation at 1000 ϫ g for 5 min. Cells were washed once with PBS and then suspended in cell lysis buffer as described above. Following clarification by centrifugation at 13,000 ϫ g for 15 min, cell lysates were measured for GFP fluorescence using a POLARstar Galaxy fluorescence plate reader (BMG LABTECH GmbH). Cell lysates prepared from the non-adherent cells were also subjected to immunoblotting for FLAG-ZIPK with anti-FLAG antibody.
RESULTS
Identification of ZIPK Autophosphorylation Sites-It was
shown previously that ZIPK undergoes autophosphorylation; but the sites of phosphorylation were not identified, and their function was not addressed (5) . Therefore, we sought to identify all ZIPK phosphorylation sites in the full-length enzyme and to determine their significance. To this end, we transiently expressed full-length FLAG-tagged ZIPK in HEK293 cells, immunoprecipitated the enzyme with anti-FLAG antibody, and eluted it with a FLAG peptide to obtain a highly pure enzyme preparation (Ͼ90% as judged by silver staining) (Fig. 1A ). If incubated with [␥-32 P]ATP in vitro, purified ZIPK was found to readily autophosphorylate at serine and threonine residues (Fig. 1A) . Autophosphorylation activity was abolished following mutation of Asp 161 to Ala (Fig. 1A) . Asp 161 is part of the highly conserved DFG sequence that comprises the so-called "T-loop" of subdomain VII found in all protein kinases, and loss of this residue is likely to cause disruption of catalytic activity because of the involvement of the DFG sequence in the coordination of Mg 2ϩ with the ␣-and ␤-phosphates of ATP (22) . In vivo labeling of ZIPK with [
32 P]orthophosphate showed that WT ZIPK underwent autophosphorylation in intact cells, and expression of the D161A mutant of ZIPK indicated that the majority of ZIPK phosphorylation under basal conditions was due to ZIPK autophosphorylation (Fig. 1A) .
To identify both the in vitro autophosphorylation and in vivo phosphorylation sites in ZIPK, the in vitro autophosphorylated enzyme and the enzyme isolated from 32 P-labeled HEK293 cells were digested with trypsin. The phosphotryptic peptides were resolved by reverse-phase HPLC and collected, and the radioactivity was measured. Four distinct peaks of radioactivity were recovered from the tryptic cleavage of both the in vitro autophosphorylated and in vivo phosphorylated enzymes (Fig.  1, B and D, respectively) , suggesting that the same sites are labeled in both proteins. The major difference between the in vitro and in vivo phosphorylated enzymes was the presence of an additional peak (fraction 27) present only in the in vitro phosphorylated enzyme (Fig. 1B) . Phosphoamino acid analysis of fraction 27 revealed the presence of phosphothreonine and phosphotyrosine, and Edman degradation and 32 P cycle release determined that the tyrosine phosphorylation occurred within the FLAG peptide sequence (data not shown). In agreement with this result, phosphoamino acid analysis of Myc-tagged ZIPK (which does not contain tyrosine in its epitope) did not reveal any phosphotyrosine (data not shown).
To identify the phosphorylation sites in ZIPK, the phosphopeptides generated from the tryptic cleavage of ZIPK were cross-linked to Immobilon-P, and any radioactivity released after each round of Edman cycling was measured. As shown in Fig. 1G , the majority of the radioactivity was detected in cycles 3 and 5, with some radioactivity also detected in cycle 4 of fractions 23 and 32. Using the CRP algorithm (23, 24) , we identified all possible serine and threonine residues that are 3, 4, or 5 amino acids away from an arginine or lysine (the cleavage site for trypsin). This analysis identified 15 (Fig. 1C) . Phosphotryptic fraction 30 contained a cycle 3 and 5 release, and phosphoamino acid analysis indicated that only phosphothreonine was present (Fig. 1, G To further narrow down the number of phosphorylation sites, autophosphorylated ZIPK was digested with chymotrypsin, and the resulting peptides were resolved by HPLC (Fig.  1E) . In this case, four major peaks of radioactivity were identified, and Edman analysis of HPLC fractions 5, 22, 29, and 32 detected radioactivity at cycles 2, 1, 6, and 8, respectively (Fig.  1, E and H) . Phosphoamino acid analysis of chymotryptic fraction 5 indicated that it contained only phosphothreonine ( Fig.  1F ) and generated a cycle 2 release, unambiguously identifying Thr 180 as a ZIPK phosphorylation site (Fig. 1H) . Although we could not unequivocally identify other phosphorylation sites from the chymotryptic digest of ZIPK, an Edman cycle release at positions 1, 6, and 8 is consistent with phosphorylation of Thr 306 , Ser 311 , and Thr 225 , respectively (Fig. 1H ). To further narrow down the number of possible ZIPK phosphorylation sites, Ser-to-Ala and Thr-to-Ala point mutations were introduced at the putative phosphorylation sites. All of the ZIPK mutants generated in this study are shown schematically in Fig. 2 . Each of the mutant proteins was then expressed in and purified from HEK293 cells, incubated with [␥-32 P]ATP, resolved by SDS-PAGE, and digested with trypsin. The resultant peptides were resolved by HPLC, and the profiles were compared with that of WT ZIPK (Fig. 3) . The T225A mutation resulted in a decrease in radioactivity in fraction 30 (Fig. 3) , a fraction that contained only phosphothreonine and generated a cycle 3 release upon Edman degradation, identifying Thr 225 as a ZIPK phosphorylation site. In contrast, mutation of a nearby residue (T227A) had no effect on the phosphotryptic HPLC profile, and a cycle 5 release by Edman degradation was still obtained (data not shown). This result indicates that the cycle 5 release obtained from fraction 30 (Fig. 1G ) was due to phosphorylation of Thr 180 and not Thr 227 . Although the T265A mutation reduced the overall phosphorylation of ZIPK, most of the reduced radioactivity was in fractions 30 and 32 (Fig. 3) , suggesting that it is also a ZIPK phosphorylation site. The T299A and T300A mutations eliminated radioactivity in frac- tion 20 (Fig. 3) , indicating that one or both of these sites are ZIPK phosphorylation sites. Thr 299 is most likely the phosphorylation site since Edman degradation of fraction 20 resulted in a cycle 3 release, which is consistent with phosphorylation of Thr 299 (Fig. 1G) . The T306A mutation eliminated the radioactivity in fraction 30, but did not affect the rest of the HPLC profile, indicating that Thr 306 is also a ZIPK phosphorylation site. To determine whether other phosphorylation sites are present outside the catalytic domain of ZIPK, we compared the phosphotryptic HPLC profile of WT ZIPK with those of S414A (chosen because it fits the consensus sequence for a ZIPK phosphorylation site of (K/R)XX(S/T)) and ZIPK⌬342 (with the last 112 amino acids removed). Both of these mutants were identical to WT ZIPK (Fig. 3) (Fig. 2) . We did not find additional evidence for phosphorylation of Ser 51 , Ser 52 , Ser 57 , Thr 112 , or Ser 288 ; and therefore, these residues were not further pursued in this study.
To confirm the ZIPK phosphorylation sites, we subjected HPLC fractions produced from the tryptic cleavage of autophosphorylated ZIPK to ESI-MS. Analysis of HPLC fraction 32 revealed two doubly charged peptides with a molecular mass difference of 40 Da (m/z 911.4053 and 951.3846 Da) (Fig. 4A) , suggesting the presence of a phosphopeptide. Direct sequencing of these peptides by ESI-MS/MS revealed that they are the same peptide with sequence 309 SHSSLPPNNSYAD-FERFSK 327 . However, the peptide at m/z 951.3846 did not contain the mass of serine at position 311 (87 Da), but instead a mass of 69 Da was detected (Fig. 4B) . A mass of 69 Da is equivalent to the mass of dehydroalanine and is indicative of loss of a phosphate group from a serine residue, unambiguously identifying Ser 311 as a ZIPK phosphorylation site (Fig. 4B) . We also detected a minor amount of peptide 309 SHSSLPPNNSY-ADFERFSK 327 in a diphosphorylated form, but were unable to determine the sites of phosphorylation because of its low abundance. This analysis, together with Edman degradation of fraction 32, which yielded radioactivity at cycles 3 and 4, suggests that the major site of phosphorylation is Ser 311 , with a minor amount of phosphorylation of Ser 312 . We also subjected unfractionated autophosphorylated ZIPK to ESI-MS and found two doubly charged peptides differing by a mass of 40 Da at m/z 772.3275 and 812.3014 (Fig. 4D) were not phosphorylated (Fig. 4E ), indicating that Thr 265 is the phosphorylation site. To confirm that Thr 265 and Ser 311 were phosphorylated in vivo, ZIPK was expressed in HEK293 cells, purified, and digested with trypsin, and the unfractionated peptides were analyzed by ESI-MS. Phosphopeptides were found and sequenced at m/z 915.3846 and 812.3014 (Fig. 4, C  and F, respectively) , confirming that Ser 311 and Thr 265 are both phosphorylated in vivo. Surprisingly, we also detected and sequenced the same phosphopeptides at m/z 951.3846 and 812.3014 (corresponding to phospho-Ser 311 and phosphoThr 265 , respectively) in the kinase-dead ZIPK mutant D161A (data not shown), indicating that it is also phosphorylated at these sites in vivo. The most likely explanation for the presence of phosphate in these sites is through phosphorylation as a result of dimerization with native ZIPK (data supporting this hypothesis are shown below).
ZIPK Activity Is Positively Regulated by Phosphorylation-To determine the effect of individual phosphorylation site mutants on total protein phosphorylation, each of the purified ZIPK mutants was incubated with [␥-32 P]ATP, resolved by SDS-PAGE, and subjected to autoradiography (Fig. 5A) . Analysis of the autoradiograms showed that mutations T180A, T225A, and T265A reduced the autophosphorylation of the proteins compared with WT ZIPK. In contrast, mutation T227A had no effect on ZIPK autophosphorylation, suggesting that mutation T225A does not simply affect protein folding. Although mutation T225D did not restore the autophosphorylation of ZIPK, mutation T180D did result in a partial restoration of ZIPK autophosphorylation, suggesting that aspartic acid may mimic phosphorylation of this site. Mutations T299A/ T300A and T306A partially reduced the autophosphorylation of ZIPK, but mutation S311A had a negligible effect (Fig. 5A) . Interestingly, mutation of the leucine zipper domain in ZIPK (V427A/V434A/L441A) increased the autophosphorylation of the enzyme compared with WT ZIPK (Fig. 5A) . Removal of the C-terminal 112 amino acids of ZIPK (ZIPK⌬342) generated proteins with apparent molecular masses on SDS-polyacrylamide gel of ϳ45 and ϳ47 kDa, with both forms undergoing autophosphorylation (Fig. 5A) . In contrast, removal of the Cterminal 181 amino acids of ZIPK (ZIPK⌬273) dramatically reduced the autophosphorylation of the enzyme most likely because the Thr 299 , Thr 306 , and Ser 311 autophosphorylation sites were removed.
To investigate the relative roles of these phosphorylation sites in ZIPK enzyme activity toward exogenous substrates, we compared the abilities of WT and mutant ZIPKs to phosphorylate the MYPT1 and LC20 (myosin regulatory light chain of 20 kDa) peptide substrates in vitro. Consistent with the autophosphorylation data, mutations T180A, T225A, and T265A dramatically reduced ZIPK activity (Fig. 5B) . However, the individual mutations T299A, T306A, and S311A had only a modest effect on enzyme activity (ϳ1.5-fold activation) (Fig.  5B) . Removal of the C-terminal 112 amino acids (ZIPK⌬342) activated the enzyme, suggesting that the C terminus acts as an inhibitory domain. Removal of the C-terminal 181 amino acids (ZIPK⌬273) further activated ZIPK, suggesting an inhibitory domain between amino acids 273 and 342 (Fig. 5B) . Interestingly, mutation V427A/V434A/L441A, which comprises the leucine zipper domain of ZIPK, resulted in a 2-3-fold activation of the enzyme.
To further investigate the role of each site in the regulation of ZIPK activity, we compared the activity of ZIPK that was allowed to preincubate with ATP at 4°C (to promote autophosphorylation) with the activity of ZIPK that was not preincubated with ATP. Determination of the stoichiometry of phosphorylation under these conditions showed that 6 Ϯ 2.7 mol of phosphate/mol of protein (S.D., n ϭ 3) was incorporated into the WT enzyme within 10 min of addition of ATP. This level of phosphorylation is consistent with phosphorylation of ZIPK at six or more sites. As shown in Fig. 5C , preincubation of ZIPK with ATP resulted in an acute 2-3-fold increase in its activity toward the myosin light chain peptide. Preincubation with ATP also activated the individual phosphorylation site mutants T299A, T306A, and S311A (Fig. 5C ), indicating that phosphorylation of these sites is not required for enzyme activation. Consistent with this result, the C-terminally truncated mutant ZIPK⌬273, which does not contain Thr 299 , Thr 306 , and Ser 311 , was also activated by preincubation with ATP, suggesting that the sites of phosphorylation responsible for activation reside in the kinase domain. The finding that preincubation with ATP caused activation of all of the mutants examined, including ZIPK⌬273, coupled with analysis of the stoichiometry of phosphorylation, strongly supports a role for Thr 180 The Intracellular Localization of ZIPK Is Regulated by Phosphorylation-To determine whether phosphorylation of ZIPK affects its intracellular location, we expressed individual phosphorylation site mutants of ZIPK and analyzed their subcellular distribution by immunofluorescence microscopy. In agreement with a recent report (4), we found that WT ZIPK localized predominantly to the cytoplasm of HeLa cells (Fig. 6) . Many of the ZIPK-transfected cells had undergone cell rounding, membrane blebbing, and DNA fragmentation; and in these cases, it was not possible to assign the localization of ZIPK. Expression of the kinase-dead ZIPK mutant D161A showed a cytoplasmic localization, but the cell rounding and membrane blebbing phenotypes associated with WT ZIPK were absent (Fig. 6) . The ZIPK mutants T180A and T225A, which displayed reduced kinase activity in vitro, were similar to kinase-dead ZIPK and localized to the cytoplasm with a normal cell morphology. The ZIPK phosphorylation site mutants T306A and S311A also exhibited a cytoplasmic localization identical to that of WT ZIPK, indicating that these phosphorylation sites, at least by themselves, do not regulate the intracellular localization of ZIPK. The C-terminally truncated ZIPK mutants (ZIPK⌬273 and ZIPK⌬342) exhibited a diffuse staining throughout the cell and caused severe cell rounding and membrane blebbing in nearly all transfected cells. This is in agreement with a previous report showing that removal of the C-terminal domain results in increased cell death (5) . Interestingly, two ZIPK mutants (T299A/T300A and V427A/V434A/L441A) were predominantly localized to the nucleus. To further address the role of Thr 299 phosphorylation in ZIPK localization, we expressed T299A and T299D (to mimic phosphorylation) and tested their localization. The T299A mutant exhibited a diffuse staining throughout the cell, but the T299D mutant exhibited a largely cytoplasmic localization. These results suggest that phosphorylation of Thr 299 and possibly Thr 300 promotes the cytoplasmic localization of ZIPK.
ZIPK Phosphorylation Affects Enzyme Activity in Vivo-As mentioned above, a proportion of WT (but not kinase-dead) ZIPK-transfected cells exhibited severe cell rounding. Not surprisingly, expression of WT ZIPK in HEK293 cells also caused many of the cells to round up and become detached from the tissue culture plate. Therefore, we used the degree of cell adherence as an unbiased and quantitative assessment of ZIPK activity in vivo. HEK293 cells were transfected with DNA encoding ZIPK along with DNA encoding GFP. Twenty-four h after transfection, the culture medium was collected, and the non-adherent cells were collected by centrifugation. The resultant cell pellets (representing the non-adherent cells only) were lysed in a fixed volume of lysis buffer, and the lysates were clarified by centrifugation. The supernatants were then measured for GFP fluorescence and for the presence of ZIPK by immunoblotting. As shown in Fig. 7 , expression of WT (but not kinase-dead) ZIPK caused a significant number of cells to become non-adherent as measured by the amount of ZIPK and GFP protein in the non-adherent cells (Fig. 7, A and B, respectively) . Expression of the ZIPK mutants T180A, T225A, and T265A dramatically reduced the amount of ZIPK and GFP in the non-adherent cells, indicating loss of ZIPK activity in vivo. Interestingly, expression of the ZIPK mutant T225D showed a slight increase in the amount of ZIPK and GFP protein recovered in non-adherent cells (Fig. 7B) , suggesting some restoration of kinase activity in vivo. In contrast, expression of T299A, T306A, or S311A did not cause a significant difference in the amount of ZIPK or GFP recovered from the non-adherent cells compared with expression of WT ZIPK, suggesting that these mutations do not affect enzyme function in vivo. In the nonadherent cell assay, expression of ZIPK⌬342 or ZIPK⌬273 showed a similar or lower activity compared with expression of WT ZIPK, which is in contrast to the results obtained with the kinase activity assays in vitro. However, as shown in Fig. 6 , nearly all cells expressing ZIPK⌬342 or ZIPK⌬273 underwent extreme cell rounding, membrane blebbing, and DNA fragmentation; and therefore, it is likely that many of these cells were not recovered in this assay due to cell death.
The Leucine Zipper Domain of ZIPK Affects Its Oligomerization-As shown above, mutation of the leucine zipper motif in the C terminus of ZIPK resulted in the activation of the enzyme compared with the WT enzyme with regard to both autophosphorylation and kinase activity toward the MYPT1 and LC20 peptides (Fig. 5) . These results suggest that the leucine zipper domain may have an inhibitory function in ZIPK. It was reported previously that the leucine zipper of ZIPK is required for ZIPK dimerization (5) . Therefore, we sought to determine whether the leucine zipper is required for ZIPK oligomerization and to determine whether phosphorylation regulates this process. To this end, we coexpressed Myc-ZIPK and FLAG-ZIPK in HEK293 cells and tested their ability to associate by co-immunoprecipitation. We found that Myc-ZIPK was able to associate with FLAG-ZIPK (Fig. 8) , indicating that the enzyme can oli- gomerize. The oligomerization of ZIPK did not require its kinase activity as shown by an equal co-immunoprecipitation of the kinase-dead mutant of ZIPK (Fig. 8) . In addition, none of the phosphorylation site mutants (T180A, T225A, T265A, T299A, T306A, and S311A) showed any decrease in their ability to associate with WT ZIPK (data not shown), indicating that phosphorylation of ZIPK is not required for oligomerization. In contrast, mutation of the leucine zipper motif dramatically reduced, but did not completely eliminate, the ability of ZIPK to oligomerize, in agreement with a previous report (5) . However, because the oligomerization of ZIPK was not completely eliminated by mutation of the leucine zipper motif, we tested whether the kinase domain itself could oligomerize. To this end, we coexpressed Myc-ZIPK⌬342 and FLAG-ZIPK⌬342 or Myc-ZIPK⌬342 and FLAG-ZIPK⌬273, all of which lack a Cterminal domain, and performed co-immunoprecipitation. Interestingly, Myc-ZIPK⌬342 was found to associate with both FLAG-ZIPK⌬342 and FLAG-ZIPK⌬273 (Fig. 8) , indicating that the C-terminal domain is not required for oligomerization. DISCUSSION ZIPK, a unique member of the DAPK family of enzymes, has been linked to several cell processes, including cell death, cell motility, and smooth muscle contractility. In smooth muscle, ZIPK is a critical regulator of myosin light chain phosphorylation as a result of phosphorylation of myosin light chain phosphatase (2, 15, (17) (18) (19) , phosphatase inhibitory proteins (21), or myosin light chain itself (1, 2, 12) . Thus, ZIPK activity could have a profound impact on smooth muscle contractility or on motility and cytoadherence in non-muscle cells. Despite these findings, the mechanism of regulation of ZIPK is poorly understood. To provide a molecular framework for understanding ZIPK regulation, we undertook a study to determine the role of phosphorylation in modulating ZIPK function. In this work, we have described for the first time that ZIPK activity is positively regulated by phosphorylation, that phosphorylation can control the localization of the enzyme, and that ZIPK activity is constrained by an inhibitory C-terminal domain. It was reported previously that ZIPK can undergo autophosphorylation; but the phosphorylation sites were not identified, and the effect of phosphorylation on enzyme activity was not determined (2, 5 (27) andphosphorylationofCa 2ϩ /calmodulindependent protein kinases I and IV within the T-loop by Ca 2ϩ / calmodulin-dependent protein kinase kinase (26) . Upon phosphorylation, the T-loop is thought to undergo a conformational change that stabilizes the kinase in an activated state (28 -31) . The importance of Thr 180 in the regulation of ZIPK is supported by enzymatic studies in which the kinase domain of ZIPK only (ZIPK⌬273) autoactivates in the presence of ATP and, more convincingly, by the finding that the ZIPK mutant T180A is completely resistant to activation. It remains to be determined whether kinases other than ZIPK itself can phosphorylate ZIPK at Thr 180 under conditions in which ZIPK may become activated (e.g. in the regulation of smooth muscle contraction).
Thr 225 and Thr 265 represent novel phosphorylation sites possibly unique to ZIPK and other members of the DAPK family. A regulatory role for phosphorylation of Thr 225 is supported by the finding that the T225A mutant of ZIPK has negligible activity both in vitro and in vivo. The effects of the T225A mutation do not appear to be related to disruption of the overall kinase structure because mutation of a nearby residue (T227A) had no effect on ZIPK activity. Additionally, the T225D mutant showed some restoration of activity when measured in a cytoadherence assay. Mutation T265A also caused a dramatic reduction in kinase activity in vitro and in vivo. We conclude that phosphorylation of Thr 180 , Thr 225 , and Thr 265 within the kinase domain represents a potential regulatory mechanism for controlling ZIPK activity in vivo.
Three phosphorylation sites were identified in the C-terminal domain: Thr 299 , Thr 306 , and Ser 311 . However, these phosphorylation sites do not have a significant effect on the activity of ZIPK. Individual mutation of Thr 299 , Thr 306 , or Ser 311 to alanine resulted in only modest increases in activity (ϳ1.5-fold) when assayed for myosin light chain phosphorylation in vitro. Moreover, phosphopeptide mapping studies showed a selective absence of a radioactive peak associated with each of the mutated sites, without effect on other autophosphorylation sites. This finding contrasts with mutations of Thr 180 , Thr 225 , and Thr 265 , which generally suppressed the autophosphorylation of all sites. The individual mutants T299A, T306A, and S311A (as well as the kinase domain only, which would remove all three sites at once) were all activated by preincubation with ATP, indicating that phosphorylation of these sites is not required for activity. Finally, in contrast to T180A, T225A, and T265A, we observed no significant difference in the ability of WT ZIPK, T299A, T306A, or S311A to affect cell adherence.
Although phosphorylation of Thr 299 did not have an appreciable effect on enzyme activity, we did find that it is involved in regulating the intracellular localization of ZIPK. Mutation T299A/T300A resulted in the nuclear localization of ZIPK compared with a cytoplasmic distribution for WT ZIPK. Consistent with this model, the T299A mutant was evenly distributed between the cytoplasm and nucleus, whereas the T299D mutant was cytoplasmic. In contrast to T299A, the T306A and S311A mutants were cytoplasmic, suggesting that these residues are not involved in regulating ZIPK localization. It should be noted that five of the six phosphorylation sites we identified in ZIPK are completely conserved in other members of the DAPK family (Fig. 9) , suggesting that similar mechanisms of regulation are possible for those enzymes (32) .
During the preparation of this manuscript, a report appeared describing the phosphorylation of ZIPK by DAPK and the identification of several ZIPK phosphorylation sites (10 32 P labeling and Edman degradation or mass spectrometry. It is possible that ZIPK does not undergo phosphorylation by DAPK in vivo under our conditions. Another explanation may be that, in the report by Shani et al. (10) , none of the phosphorylation sites were directly identified, but rather were inferred by mutagenesis. Indeed, apart from the present study, only one phosphorylation site has been directly identified in any of the DAPKs, that being Ser 308 in DRP-1 by mass spectrometry (33) , which corresponds to Thr 306 in ZIPK (Fig. 9) . The function of ZIPK phosphorylation at Thr 299 , Ser 309 , Ser 311 , Ser 312 , Ser 318 , and Ser 326 was concluded to be activating because mutation of all six sites to aspartic acid increased the apoptotic effects of the enzyme (10). However, because the authors mutated all six sites together, it is unclear which sites are responsible for regulating ZIPK function. In addition, because the enzyme activity of the ZIPK mutants were not measured (10), it is unclear what effect these mutations have, if any, on the enzyme activity of ZIPK. It was also concluded that phosphorylation of one or more of the six identified sites promotes the cytoplasmic localization of ZIPK (10). Although we found no role for the regulation of ZIPK localization through phosphorylation of Thr 306 or Ser 311 , we did find that phosphorylation of Thr 299 promotes the cytosolic distribution of ZIPK.
We have shown here that removal of the C-terminal domain of ZIPK results in its activation. These enzymatic data correlate with previous reports showing that C-terminal truncation of ZIPK results in increased cell death (34, 35) . The finding that ZIPK⌬273 has more activity than ZIPK⌬342 argues for the presence of an inhibitory domain between amino acids 273 and 342, and this region is where three of the identified phosphorylation sites reside (Thr 299 , Thr 306 , and Ser 311 ). However, phosphorylation does not appear to be required for its inhibitory action because mutation of Thr 299 , Thr 306 , and Ser 311 to alanine had little effect on activity.
It was shown previously that mutation of the leucine zipper of ZIPK (V427A/V434A/L441A) results in loss of self-association, autophosphorylation, and decreased ability of the enzyme to induce cell death when overexpressed in NIH3T3 cells (5) . In agreement with this report, we found that mutation of the leucine zipper severely compromised the ability of ZIPK to oligomerize. Paradoxically and in contrast to the report by Kawai et al. (5) , we found that mutation of the leucine zipper resulted in increased enzyme activity as measured by autophosphorylation and substrate phosphorylation. One explanation for this discrepancy may be that the leucine zipper mutant is localized predominantly in the nucleus compared with WT ZIPK, which is cytoplasmic. A nuclear localization for the leucine zipper mutant may prevent its interaction with cytoplasmic substrates (such as MYPT1 and myosin light chain) that may be involved in mediating loss of cytoadherence and cell death. Interestingly, although mutation of the leucine zipper of ZIPK compromised its ability to oligomerize in the fulllength enzyme, we found that the ZIPK kinase domain itself was sufficient for oligomerization. This finding is in agreement with the conclusions of Shani et al. (10) showing that the kinase domains of ZIPK and DAPK (which are 80% identical) can associate.
